Report Highlights

North America Propolis Market: Market Overview

The North American propolis market is valued at USD 312.4 million in 2024 and is structured across three primary verticals: dietary supplements, oral care products, and natural cosmetics. Government policy has been the primary determinant of market structure rather than private sector innovation. In the United States, the Dietary Supplement Health and Education Act of 1994 (DSHEA) established the foundational legal framework under which propolis products are sold, prohibiting disease claims while permitting structure-function claims that drive label differentiation. The result is a supplement-dominated market where private-label formulators account for nearly 55% of domestic retail volume, with brands such as Y.S. Eco Bee Farms and Beekeeper's Naturals leading branded segments through compliant positioning strategies.

Canada's market is governed under the Natural Health Products Regulations (SOR/2003-196), which requires each propolis product to carry a Natural Product Number (NPN) issued by Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD). This licensing requirement has created a more consolidated Canadian market compared to the United States, with fewer but more rigorously vetted SKUs in retail channels. Mexico operates under COFEPRIS authority, where propolis is classified within the broader herbal supplement category subject to NOM-073-SSA1 standards for stability testing. The structural divergence across the three regulatory jurisdictions prevents harmonised product launches and increases compliance overhead for manufacturers seeking pan-regional distribution, effectively fragmenting what would otherwise be a single integrated market.

Policy-Driven Growth in North American Propolis

Three specific policy mechanisms are actively driving demand across the North American propolis market. First, the United States National Organic Program (NOP), administered by the USDA Agricultural Marketing Service under 7 CFR Part 205, has driven significant growth in certified organic propolis products. Certified organic propolis commands a 30–40% price premium in retail, and consumer demand for NOP-certified natural health products increased by 12% between 2021 and 2023 according to USDA Organic Survey data. This certification mechanism directly translates into market growth by enabling premium positioning that supports higher retail margins, incentivising producers to invest in certified supply chains from domestic apiaries in states including California, Oregon, and Florida.

Second, the United States 2018 Farm Bill (Public Law 115-334) included specific provisions supporting apiculture research and beekeeper development through the Specialty Crop Block Grant Program and the Emergency Assistance for Livestock, Honeybees, and Farm-Raised Fish (ELAP) programme, providing up to USD 20 million annually in beekeeper support. This indirectly stabilises domestic propolis supply by reducing apiary collapse risks tied to colony loss events. Third, Health Canada's 2022 update to the Natural Health Products Ingredients Database (NHPID) expanded the permitted evidence base for propolis efficacy claims, allowing references to antimicrobial and immune-modulating properties under a monograph framework. This regulatory liberalisation has enabled Canadian manufacturers to launch new propolis-based oral spray and throat lozenge products without full clinical trial requirements, accelerating product development cycles.

Regulatory Barriers and Compliance Costs

The most significant regulatory barrier for propolis market participants in the United States is the FDA's Current Good Manufacturing Practice (cGMP) requirements under 21 CFR Part 111, administered by the FDA's Center for Food Safety and Applied Nutrition (CFSAN). Compliance with Part 111 requires documented identity testing of raw propolis inputs, which is technically demanding due to propolis's chemically variable composition across botanical and geographic origins. Third-party cGMP audits cost between USD 15,000 and USD 40,000 annually depending on facility size, and the FDA issued warning letters to three dietary supplement manufacturers in 2022 for identity testing failures involving botanical ingredients, creating precedent-based compliance anxiety across the propolis supply chain. Smaller domestic producers and importers operating below USD 5 million in annual revenue face disproportionate cost burdens relative to large incumbents with established quality infrastructure.

Canada imposes a distinct barrier through Health Canada's product licence application process under SOR/2003-196. Each NPN application requires a site licence for the manufacturing facility in addition to the product licence, and Health Canada's NNHPD has reported average review timelines of 155–180 calendar days for Class III natural health products, which includes most propolis formulations with therapeutic claim language. In Mexico, COFEPRIS's sanitary registration process under the Reglamento de Insumos para la Salud requires stability testing data per NOM-073-SSA1, adding four to six months and approximately USD 8,000–12,000 in laboratory testing costs per SKU. These staggered national timelines make simultaneous multi-market launches economically impractical for companies without dedicated regulatory affairs teams, creating a structural advantage for well-capitalised incumbents over emerging brands.

Policy-Created Opportunities in North American Propolis

The most immediate policy-created opportunity in the North American propolis market arises from the USDA's Organic Transition Initiative, announced in 2023 with USD 300 million in funding under the Inflation Reduction Act (Public Law 117-169). This programme incentivises conventional apiary operators to transition to certified organic practices, which directly expands the domestic certified organic propolis supply pool. As organic propolis currently represents less than 18% of North American supply but commands premium retail pricing, any expansion of certified supply will enable manufacturers to introduce organic-positioned propolis product lines that address unmet retail demand, particularly in the natural food channel through retailers such as Whole Foods Market and Natural Grocers.

A second structural opportunity is created by Health Canada's ongoing review of the Natural Health Products Regulations, launched in 2021 under a modernisation initiative expected to produce revised regulations by 2026. The proposed changes include a new risk-based product categorisation system that would reduce licensing burden for low-risk topical propolis products such as lip balms and skin creams, potentially creating a fast-track pathway with approval timelines under 60 days. Additionally, Mexico's COFEPRIS has signalled alignment with Codex Alimentarius standards for apitherapy products, which, if formalised through NOM revision, would allow propolis exporters with existing Codex-aligned documentation to seek Mexican registration without duplicating stability study requirements, materially reducing entry costs for US-based manufacturers targeting the Mexican natural health market.

Market at a Glance

Leading Market Participants

• Beekeeper's Naturals
• Y.S. Eco Bee Farms
• Swanson Health Products
• NOW Foods
• Nature's Answer
• Comvita Limited
• Apis Flora
• Bee Health Limited
• Holista CollTech
• Source Naturals

Regulatory and Policy Environment

The primary legislation governing propolis in the United States is the Dietary Supplement Health and Education Act of 1994 (DSHEA), codified at 21 U.S.C. §321(ff), administered by the FDA's Center for Food Safety and Applied Nutrition. Under DSHEA, propolis manufacturers must submit a New Dietary Ingredient (NDI) notification to CFSAN if the ingredient was not marketed before October 15, 1994, or if a material change in manufacturing process creates a new ingredient profile. The FDA's NDI Draft Guidance, updated in 2016, specifies that propolis extracts standardised to novel flavonoid concentrations warrant NDI review, a requirement that has created regulatory uncertainty for companies innovating propolis extraction technology. Key upcoming regulatory changes include the FDA's anticipated finalisation of its New Dietary Ingredient guidance, expected in 2025, which will clarify notification thresholds and directly affect propolis formulation strategies across the supplement industry.

Compared to regional peers, North America's propolis regulatory framework is notably more prescriptive than Brazil's ANVISA framework under RDC Resolution 240/2018, which provides a dedicated apitherapy product category with streamlined registration pathways. The European Union's approach under Regulation (EC) No 1924/2006 on nutrition and health claims similarly provides greater category specificity than DSHEA's general structure-function claim model, leaving US manufacturers with less regulatory clarity around permissible efficacy language. Canada's NHP Regulations represent a middle path, offering more category-specific guidance than DSHEA while remaining less burdensome than full pharmaceutical registration. For market participants, this creates a situation where Health Canada's monograph-based approval system for propolis is the most operationally predictable pathway in the North American region, and manufacturers that build compliance infrastructure around the Canadian NHP framework gain a transferable regulatory dossier applicable to other markets with similar evidence standards.

Long-Term Policy Outlook for North American Propolis

By 2032, the most consequential policy development shaping the North American propolis market will be the FDA's potential reclassification of certain concentrated propolis extracts under the New Dietary Ingredient framework, particularly if the agency finalises stricter NDI notification requirements as proposed in its 2022 regulatory agenda. A stricter NDI framework would raise the cost of launching novel propolis formulations and consolidate market share among established supplement manufacturers with existing pre-DSHEA documentation, effectively creating a two-tier market structure where innovation is concentrated among capitalised incumbents. Additionally, the Federal Trade Commission's (FTC) ongoing crackdown on unsubstantiated health claims — reflected in its 2023 Health Products Compliance Guidance — will intensify scrutiny of propolis marketing language, requiring manufacturers to invest in clinical substantiation to maintain digital advertising access on platforms that enforce FTC standards.

In Canada, the anticipated 2026 revision to the Natural Health Products Regulations is expected to introduce a graduated licensing system that reduces compliance burden for topical and low-risk propolis products while increasing evidence requirements for ingestible immune health claims. This policy shift will redirect product development investment toward topical propolis formats — cosmetics, oral care, wound care — where regulatory pathways become faster. In Mexico, COFEPRIS's stated intention to update the NOM framework for herbal and natural health products by 2027 creates a window for US and Canadian propolis producers to engage in the standards-setting consultation process and align Mexican NOM requirements with existing North American regulatory dossiers. Collectively, these anticipated regulatory changes will reward companies that invest in multi-jurisdictional compliance infrastructure and clinical evidence generation before 2027, positioning them to capture first-mover advantage as regulatory pathways clarify across all three North American markets.

Market Segmentation

By Product Form

• Liquid Extract
• Capsules and Tablets
• Powder
• Throat Spray
• Topical Cream and Balm
• Lozenges

By Application

• Dietary Supplements
• Oral Care
• Cosmetics and Skincare
• Functional Food and Beverage
• Wound Care

By Distribution Channel

• Health Food Stores
• Online Retail
• Pharmacies and Drug Stores
• Supermarkets and Hypermarkets
• Direct-to-Consumer

By Country

• United States
• Canada
• Mexico

Frequently Asked Questions

Q1. What regulatory framework governs propolis dietary supplements in the United States? ▼

Propolis dietary supplements in the United States are governed by the Dietary Supplement Health and Education Act of 1994 (DSHEA), administered by the FDA's Center for Food Safety and Applied Nutrition. Manufacturers must comply with 21 CFR Part 111 cGMP requirements and submit New Dietary Ingredient notifications for novel propolis extract formulations.

Q2. How does Health Canada license propolis products for the Canadian market? ▼

Health Canada licenses propolis products under the Natural Health Products Regulations (SOR/2003-196), requiring each product to obtain a Natural Product Number from the NNHPD before sale. Applicants must also hold a valid site licence for any facility manufacturing, packaging, or labelling propolis products intended for Canadian consumers.

Q3. What claims can propolis manufacturers legally make in North American markets? ▼

In the United States, manufacturers may make structure-function claims under DSHEA but are prohibited from making disease claims without FDA pre-approval as a drug. In Canada, Health Canada's NHPID monograph for propolis permits claims related to antioxidant activity and oral health support when supported by referenced evidence standards.

Q4. How does the USDA National Organic Program affect propolis supply and pricing? ▼

The USDA National Organic Program under 7 CFR Part 205 requires propolis to meet certified organic standards for apiary management, feed, and pest control to carry the USDA Organic seal. Certified organic propolis commands a 30–40% retail price premium, incentivising producers but restricting supply to apiaries that complete the three-year transition period.

Q5. What upcoming regulatory changes will most affect the North American propolis market by 2027? ▼

The FDA's anticipated finalisation of its New Dietary Ingredient guidance will directly affect propolis formulation strategies by clarifying which extract concentrations trigger mandatory notification requirements. Canada's planned 2026 revision to the Natural Health Products Regulations is expected to create a fast-track pathway for topical propolis products, reducing approval timelines below 60 days.